A Novel Desensitization Protocol for Infliximab Hypersensitivity in a 13-Year Old Patient with Pustular Psoriasis

Curr Drug Saf. 2019;14(2):158-162. doi: 10.2174/1574886314666190119115632.

Abstract

Background: Drug hypersensitivity reactions to infliximab have been reported in pediatric patients. At times, these patients may need infliximab administration in spite of hypersensitivity. However, only a few reports of desensitization protocols are available in the literature in pediatric patients.

Case report: We report a case of immediate hypersensitivity reaction to intravenous infliximab in a 13-year-old child suffering from pustular psoriasis who eventually underwent a 14 step desensitization protocol for the administration of infliximab in a pediatric intensive care unit.

Results and conclusion: Although our desensitization protocol was safe and effective, we recommend the entire desensitization procedure to be performed under the supervision of experienced personnel in a pediatric intensive care unit. Future studies with larger sample size are needed to confirm our findings.

Keywords: BAT; Desensitization; infliximab; monoclonal antibody; pediatric; psoriasis..

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Desensitization, Immunologic*
  • Drug Hypersensitivity*
  • Humans
  • Infliximab / adverse effects*
  • Male
  • Psoriasis / drug therapy*

Substances

  • Infliximab